In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder

Oncology Reports

Volumn 12, Issue 4, 2004, Pages 909-913

  Bhuvarahamurthy, Venugopal ^a   Schroeder, Joerg ^a   Denkert, Carsten ^a   Kristiansen, Glen ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a   Jung, Klaus ^a   Staack, Andrea ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Immunohistochemistry; In situ hybridization; Transitional cell carcinoma; Urokinase type plasminogen activator; Urokinase type plasminogen activator receptor

Indexed keywords

CELL SURFACE RECEPTOR; MESSENGER RNA; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; UROKINASE;

AGED; ARTICLE; BLADDER TUMOR; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IN SITU HYBRIDIZATION; KIDNEY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PELVIS; PHYSIOLOGY; RNA PROBE; STROMA CELL; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; KIDNEY; MALE; MIDDLE AGED; NEOPLASM STAGING; PELVIS; RECEPTORS, CELL SURFACE; RNA PROBES; RNA, MESSENGER; STROMAL CELLS; URINARY BLADDER NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR; UROTHELIUM;

EID: 16644402997     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.4.909     Document Type: Article

References (39)

1. Van der Burg ME, Henzen-Logmans SC, Berns EM, van Putten WL, Klijn JG and Foekens JA: Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer 69: 475-479, 1996. (Pubitemid 27050525)
2. Dano K, Andreasen PA, Gröndahl HJ, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266, 1985.
3. Blasi F: Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 15: 105-111, 1993.
4. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997. (Pubitemid 27314632)
5. r 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86-92, 1985.
6. Ossowski L: In vivo invasion of modified chorioallantoic membrane bv tumor cells: the role of cell surface-bound urokinase. J Cell Biol 107: 2437-2445, 1988.
7. Casslen B, Gustavsson B and Astedt B: Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumors. Eur J Cancer 27: 1445-1448, 1991.
8. Pedersen H, Grondahl HJ, Francis D, Osterlind K, Hansen HH, Dano K, et al: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120-123, 1994. (Pubitemid 24042098)
9. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB and Verspaget HW: Urokinase receptor and colorectal cancer survival. Lancet 344: 401-402, 1994. (Pubitemid 24248215)
10. Grondahl HJ, Peters HA, van Putten WL, Look MP, Pappot H, Ronne E, et al: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1: 1079-1087, 1995.
11. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, et al: Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 75: 388-395, 1997. (Pubitemid 27051054)
12. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991. (Pubitemid 121001258)
13. Harris AL, Fox S, Leek R, Zhang H, Scott P, Bicknell R, et al: Breast cancer angiogenesis: therapy target and prognostic factor. Eur J Cancer 31A: 831-832, 1995.
14. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
15. Fazioli F and Blasi F: Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci 15: 25-29, 1994. (Pubitemid 24027447)
16. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y and Sumiyoshi A: The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 50: 871-873, 1992.
17. Hudson A and McRenolds LM: Urokinase and the urokinase receptor. Association with in vitro invasiveness of human bladder cancer cell lines. J Natl Cancer Inst 89: 709-717, 1997.
18. Brunner G, Pohl J, Erkell LJ, Radier PA and Schirrmacher V: Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene. J Cancer Res Clin Oncol 115: 139-144, 1989. (Pubitemid 19109370)
19. Sobin LH and Wittekind C: TNM classification of malignant tumors. 5th edition. Wiley-Liss, New York, 1997.
20. Axelrod JH, Reich R and Miskin R: Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. Mol Cell Biol 9: 2133-2141, 1989. (Pubitemid 19117814)
21. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, et al: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467-474, 1990.
22. Hogan B, Constantini F and Lacy E: Manipulating the mouse embryo. Visualizing genes and gene products. Cold Spring Harbor Laboratory Press, 1986.
23. Schmitt M, Chucholowski N, Busch E, Hellmann D, Wagner B, Goretzki L, et al: Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cells. Semin Thromb Hemost 17: 291-302, 1991.
24. Evans CP, Elfman F, Parangi S, Conn M, Cunha G and Shuman MA: Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 57: 3594-3599, 1997. (Pubitemid 27355512)
25. Mitsubayashi S, Akiyama T, Kurita T, Okada K, Bando H, Sakai T, et al: Plasminogen activator in bladder tumors. Urol Res 15: 335-339, 1987. (Pubitemid 18041691)
26. Hasui Y, Suzumiya J, Marutsuka K, Sumiyoshi A, Hashida S and Ishikawa E: Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder. Cancer Res 49: 1067-1070, 1989. (Pubitemid 19064370)
27. Sappino AP, Belin D, Huarte J, Hirschel SS, Saurat JH and Vassalli JD: Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88: 1073-1079, 1991.
28. Miller SJ, Jensen PJ, Dzubow LM and Lazarus GS: Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. J Invest Dermatol 98: 351-358, 1992.
29. Yamamoto M, Sawaya R, Mohanam S, Rao VH, Bruner JM, Nicolson GL, et al: Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 54: 5016-5020, 1994. (Pubitemid 24289437)
30. Wagner SN, Atkinson MJ, Thanner S, Wagner C, Schmitt M, Wilhelm O, et al: Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am J Pathol 147: 183-192, 1995.
31. Pyke C, Kristensen P, Ralfkiaer E, Grondahl HJ, Eriksen J, Blasi F, et al: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067, 1991.
32. Ellis V, Pyke C, Eriksen J, Solberg H and Dano K: The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 667: 13-31, 1992. (Pubitemid 23061557)
33. Mignatti P and Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195, 1993. (Pubitemid 23065437)
34. Nakanishi K, Kawai T, Torikata C, Aurues T and Ikeda T: Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. Cancer 82: 724-732, 1998.
35. Liotta LA, Rao CN and Wewer UM: Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 55: 1037-1057, 1986. (Pubitemid 16070794)
36. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, et al: Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 53: 3198-3206, 1993. (Pubitemid 23210335)
37. Bianchi E, Cohen RL, Thor AT, Todd RF III, Mizukami IF, Lawrence DA, et al: The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861-866, 1994. (Pubitemid 24085428)
38. De Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, et al: Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144: 70-81, 1994. (Pubitemid 24158361)
39. Sier CF, Quax PH, Vloedgraven HJ, Verheijen JH, Griffioen G, Ganesh S, et al: Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases. Invasion Metastasis 13: 277-288, 1993.